Heparine Leo (Heparin Sodium)

Heparine Leo is indicated for several antithrombotic purposes in clinical practice. It is commonly employed in the following situations:

• Prevention and treatment of venous thromboembolism, including pulmonary embolism and deep‑vein thrombosis.
• Prophylaxis of deep vein thrombosis in patients undergoing major surgery.
• Management of acute coronary syndromes such as unstable angina or myocardial infarction.
• Prevention of clot formation in extracorporeal circuits, for example during dialysis or cardiopulmonary bypass.
• Use in patients at high risk of thrombotic events when rapid anticoagulation is required.

Heparine Leo may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common

• Minor bleeding at the injection site or mucosal surfaces.
• Small bruising or hematoma formation.
• Transient elevation of liver enzymes.
• Mild thrombocytopenia without clinical sequelae.

Serious

• Major hemorrhage, including intracranial or gastrointestinal bleeding.
• Heparin‑induced thrombocytopenia (HIT) with a risk of thrombosis.
• Severe allergic reactions such as anaphylaxis.
• Spontaneous spinal or epidural hematoma leading to neurologic deficits.
• Acute renal impairment associated with massive bleeding.

When prescribing or administering Heparine Leo, clinicians should consider several safety measures. Important precautions include:

• Assess patient history for prior heparin exposure or known hypersensitivity.
• Monitor activated partial thromboplastin time (aPTT) or anti‑Xa levels to maintain therapeutic range.
• Evaluate platelet counts regularly to detect possible heparin‑induced thrombocytopenia.
• Use caution in patients with active bleeding, recent surgery, or uncontrolled hypertension.
• Adjust dosing or avoid use in severe renal or hepatic impairment.
• Consider pregnancy status, as safety data are limited.
• Review concomitant use of other anticoagulants or antiplatelet agents.

Heparine Leo can interact with several other medications, affecting either its anticoagulant effect or the safety profile of the co‑administered drug.

Avoid

• Concurrent use with other parenteral anticoagulants (e.g., direct thrombin inhibitors) due to additive bleeding risk.
• Combination with potent antiplatelet agents such as clopidogrel or ticagrelor when high bleeding risk is present.
• Administration with fibrinolytic therapy (e.g., alteplase) without close monitoring.

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may increase gastrointestinal bleeding.
• Selective serotonin reuptake inhibitors (SSRIs) or other drugs affecting platelet function.
• High‑dose corticosteroids, which can potentiate mucosal bleeding.
• Certain antibiotics (e.g., vancomycin) that may alter platelet counts.